Mamographic density and disease-free survival in [HR+, HER2-] locally advanced breast cancer treated with neoadjuvant chemotherapy.

Rojas, Katerin Ingrid; Flores, R.; Flores, Claudio; Pinto, Joseph A.; Gómez, Henry Leonidas; Castañeda, Carlos A.

doi:10.1200/jco.2014.32.15_suppl.e11536

Cited by 4 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For postmenopausal patients, the trend was the same for those with BI-RADS breast composition category b and c , although none of the four patients in the BI-RADS breast composition category d achieved pCR; thus, this category was not part of the logistic regression models. Our results are in line with previous studies, claiming that MD holds predictive information for response to anticancer treatment [4, 17, 19]. This study indicates that in the neoadjuvant BC setting, especially for premenopausal women, MD may be considered when making clinical treatment decisions.…”

Section: Discussionsupporting

confidence: 92%

“…A less investigated path is MD’s role in terms of response to anticancer treatment, i.e., as a predictive factor for treatment effect explored in this study. A recent study of neoadjuvant treated patients with locally advanced BC showed that patients with low MD at diagnosis have a more favorable disease-free survival rate compared to patients with high MD [19]. A small study of 60 patients with metastatic BC showed better progression-free survival in those with low MD at diagnosis [42].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

et al. 2019

View full text Add to dashboard Cite

BackgroundOur aim is to study if mammographic density (MD) prior to neoadjuvant chemotherapy is a predictive factor in accomplishing a pathological complete response (pCR) in neoadjuvant-treated breast cancer patients.MethodsData on all neoadjuvant treated breast cancer patients in Southern Sweden (2005–2016) were retrospectively identified, with patient and tumor characteristics retrieved from their medical charts. Diagnostic mammograms were used to evaluate and score MD as categorized by breast composition with the Breast Imaging-Reporting and Data System (BI-RADS) 5th edition. Logistic regression was used in complete cases to assess the odds ratios (OR) for pCR compared to BI-RADS categories (a vs b-d), adjusting for patient and pre-treatment tumor characteristics.ResultsA total of 302 patients were included in the study population, of which 57 (18.9%) patients accomplished pCR following neoadjuvant chemotherapy. The number of patients in the BI-RADS category a, b, c, and d were separately 16, 120, 140, and 26, respectively. In comparison to patients with BI-RADS breast composition a, patients with denser breasts had a lower OR of accomplishing pCR: BI-RADS b 0.32 (95%CI 0.07–0.1.5), BI-RADS c 0.30 (95%CI 0.06–1.45), and BI-RADS d 0.06 (95%CI 0.01–0.56). These associations were measured with lower point estimates, but wider confidence interval, in premenopausal patients; OR of accomplishing pCR for BI-RADS d in comparison to BI-RADS a: 0.03 (95%CI 0.00–0.76).ConclusionsThe likelihood of accomplishing pCR is indicated to be lower in breast cancer patients with higher MD, which need to be analysed in future studies for improved clinical decision-making regarding neoadjuvant treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, patients with high BD at diagnostic mammograms had increased risk of local recurrence after mastectomy [16]. In a recent study involving 267 patients, low BD was associated with improved disease-free survival in locally advanced patients treated with neoadjuvant chemotherapy [17]. However, Castaneda et al, 2014 [18] failed to show any correlation between mammographic BD and pCR.…”

Section: Discussionmentioning

confidence: 99%

Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In addition, Rojas et al. ( 20 ) performed the same grouping in their study of MD and its association with disease free survival, thus facilitating the comparison of study results. Moreover, the inter-radiologist agreement is most significant for radiologists assessing the least dense (BI-RADS a) and most dense (BI-RADS d) categories of MD ( 35 , 36 ), thus supporting the high validity of the MD scoring for these groups.…”

Section: Methodsmentioning

confidence: 99%

“…Studies, among one by our research group ( 19 ), have suggested that extremely dense breasts (Breast Imaging-Reporting and Data System (BI-RADS) d) pre-NACT (baseline) decreases the chances of achieving pCR post-NACT, suggesting that MD could be used as a predictive marker of pCR ( 20 , 21 ). However, a recent study by Di Cosimo et al.…”

Section: Introductionmentioning

confidence: 99%

Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe association between mammographic density (MD) and breast cancer (BC) recurrence and survival remains unclear. Patients receiving neoadjuvant chemotherapy (NACT) are in a vulnerable situation with the tumor within the breast during treatment. This study evaluated the association between MD and recurrence/survival in BC patients treated with NACT.MethodsPatients with BC treated with NACT in Sweden (2005–2016) were retrospectively included (N=302). Associations between MD (Breast Imaging-Reporting and Data System (BI-RADS) 5th Edition) and recurrence-free/BC-specific survival at follow-up (Q1 2022) were addressed. Hazard ratios (HRs) for recurrence/BC-specific survival (BI-RADS a/b/c vs. d) were estimated using Cox regression analysis and adjusted for age, estrogen receptor status, human epidermal growth factor receptor 2 status, axillary lymph node status, tumor size, and complete pathological response.ResultsA total of 86 recurrences and 64 deaths were recorded. The adjusted models showed that patients with BI-RADS d vs. BI-RADS a/b/c had an increased risk of recurrence (HR 1.96 (95% confidence interval (CI) 0.98–3.92)) and an increased risk of BC-specific death (HR 2.94 (95% CI 1.43–6.06)).ConclusionThese findings raise questions regarding personalized follow-up for BC patients with extremely dense breasts (BI-RADS d) pre-NACT. More extensive studies are required to confirm our findings.

show abstract

Mamographic density and disease-free survival in [HR+, HER2-] locally advanced breast cancer treated with neoadjuvant chemotherapy.

Cited by 4 publications

References 0 publications

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients

Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy

Contact Info

Product

Resources

About